Skip to main content
Log in

Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this study was to investigate the expression and prognostic significance of NEDD9 in pancreatic ductal adenocarcinoma (PDA). Expressional levels of NEDD9 mRNA and protein in paired pancreatic cancer lesions and adjacent noncancerous tissues were examined by quantitative real-time PCR and western blotting. NEDD9 expression was analyzed by immunohistochemistry in 106 patients with PDA. The correlations between NEDD9 immunostaining levels and clinicopathologic factors, as well as the follow-up data of patients, were analyzed statistically. NEDD9 protein and mRNA levels were elevated in pancreatic carcinoma lesions compared with the paired adjacent noncancerous tissues. A high level of expression of NEDD9 was significantly correlated with clinical staging (P < 0.001), lymph node metastasis (P < 0.001), and histological differentiation (P < 0.001). Patients with a higher NEDD9 expression had a significantly shorter survival time than those patients with lower NEDD9 expression. The multivariate analysis revealed that NEDD9 could serve as an independent factor of poor prognosis. Our finding indicates that NEDD9 could be used as prognostic molecular marker and therapeutic target for PDA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671–7.

    Article  PubMed  CAS  Google Scholar 

  2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5–27.

    Article  PubMed  CAS  Google Scholar 

  3. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, et al. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP. 2006;7(5):486–91.

    PubMed  Google Scholar 

  4. Fisher WE, Berger DH. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int J Gastrointest Cancer. 2003;33(1):79–88.

    Article  PubMed  Google Scholar 

  5. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16:3327–37.

    PubMed  CAS  Google Scholar 

  6. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes. J Exp Med. 1996;184:1365–75.

    Article  PubMed  CAS  Google Scholar 

  7. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61.

    Article  PubMed  CAS  Google Scholar 

  8. Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67:1025–48. doi:10.1007/s00018-009-0213-1.

    Article  PubMed  CAS  Google Scholar 

  9. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24. doi:10.1038/nature03799.

    Article  PubMed  CAS  Google Scholar 

  10. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721–32. doi:10.1038/sj.onc.1209199.

    Article  PubMed  CAS  Google Scholar 

  11. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269–81.

    Article  PubMed  CAS  Google Scholar 

  12. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer. 1997;80:1803–4.

    Article  PubMed  CAS  Google Scholar 

  13. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979–85.

    Article  PubMed  CAS  Google Scholar 

  14. Chang JX, Gao F, Zhao GQ, Zhang GJ. Expression and clinical significance of NEDD9 in lung tissues. Med Oncol. 2012;29:2654–60. doi:10.1007/s12032-012-0213-0.

    Article  PubMed  CAS  Google Scholar 

  15. Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, et al. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997;28:65–72.

    PubMed  CAS  Google Scholar 

  16. le Thao B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther. 2009;8:683–8.

    Article  CAS  Google Scholar 

  17. Iwata S, Souta-Kuribara A, Yamakawa A, Sasaki T, Shimizu T, Hosono O, et al. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene. 2005;24:1262–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the municipal subsidy scheme of the “333 Project” research projects of Jiangsu Province (CAE01101-06), Jiangsu Chinese medicine scientific research subsidization topics (LZ11127), and social development project of Wuxi city (CNZ00N1110).

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Yu-Zheng Xue, Jian-Ping Li or Zhao-Shen Li.

Additional information

Yu-Zheng Xue, Ying-Yue Sheng, and Zong-Liang Liu contributed equally to this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xue, YZ., Sheng, YY., Liu, ZL. et al. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumor Biol. 34, 895–899 (2013). https://doi.org/10.1007/s13277-012-0624-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0624-8

Keywords

Navigation